Research
Hormonal
GLP-1 receptor agonists (e.g., Semaglutide, Liraglutide) and SGLT-2 inhibitors improve glycemic control, body weight, and cardiovascular risk factors in obese patients with type 2 diabetes.
If lifestyle changes alone are insufficient, medications like GLP-1 agonists (e.g., Semaglutide) or SGLT-2 inhibitors can help manage blood sugar and support weight loss. These are prescribed when lifestyle interventions fail to meet targets.
GoodSupportsHIGH confidence
Moderne Therapieansätze wie GLP-1-Rezeptoragonisten und SGLT-2-Inhibitoren verbessern sowohl die glykämische Kontrolle als auch das Körpergewicht und sind daher integraler Bestandteil eines kombinierten Managements [33].
Why this rating
Consensus paper citing multiple studies on specific drug classes.
Source
Management kardiovaskulärer Erkrankungen bei Adipositas
Andrea Baessler et al. · Die Kardiologie · 2026
DOI 10.1007/s12181-026-00813-8
clinical_guideline
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weight reduction of 5-15% in obese patients with cardiovascular disease leads to dose-dependent improvements in cardiometabolic risk factors, including blood pressure, lipid profiles, and glycemic control.Good
- Visceral fat accumulation is a primary driver of cardiovascular disease in obesity, independent of BMI, through inflammatory and metabolic mechanisms.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →